Pre-Travel Screen (DVT)
Private Pre-Travel DVT screening in London for £371, assessing 18 reported clot-risk and blood-count markers with results in around 5 days.
Turnaround time
5 business days
Biomarkers count
18
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : 'Free' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the Pre-Travel Screen (DVT) Test
selected inherited, immune and haematological factors associated with venous thrombosis risk before prolonged travel.
The current London Blood Tests catalogue reports 18 biomarkers across the panel.
The core laboratory components are a Full Blood Count, Factor II Prothrombin G20210A testing, Factor V Leiden G1691A testing and Cardiolipin Antibodies.
Deep vein thrombosis, or DVT, occurs when a blood clot develops within a deep vein, most commonly in the leg.
Long periods of immobility can slow venous blood flow.
This is one reason long-distance travel is associated with a small increase in venous thromboembolism risk.
Most travellers will not develop a DVT.
Risk becomes more important when travel is combined with additional factors such as a previous clot, inherited thrombophilia, recent surgery, pregnancy, Oestrogen-containing contraception, HRT, active cancer or significant immobility.
Factor V Leiden and the Prothrombin G20210A variant are two inherited genetic changes associated with increased venous thrombosis risk.
Cardiolipin Antibodies are associated with antiphospholipid autoimmunity and can be relevant to abnormal clotting when persistently positive in the appropriate clinical context.
The Full Blood Count provides general information about blood cells and Platelets.
This screen does not calculate an individual's exact probability of developing a DVT during a flight.
It also does not assess every inherited or acquired thrombophilia.
A negative panel therefore does not eliminate travel-related clot risk.
Clinical history remains essential.
What Does the Pre-Travel Screen (DVT) Contain?
The live catalogue reports 18 laboratory measurements across a Full Blood Count and three targeted thrombophilia components. This test measures 18 reported biomarkers.
Haemoglobin - Measures the oxygen-carrying protein within red blood cells.
Haematocrit - Measures the proportion of blood volume occupied by red blood cells.
Red Cell Count (RCC) - Measures the number of circulating red blood cells.
Mean Cell Volume (MCV) - Measures average red-cell size.
Mean Cell Haemoglobin (MCH) - Measures the average amount of Haemoglobin within each red blood cell.
Mean Cell Haemoglobin Concentration (MCHC) - Measures the average concentration of Haemoglobin within red blood cells.
Red Cell Distribution Width (RDW) - Assesses variation in red-cell size.
White Cell Count (WCC) - Measures the total number of circulating white blood cells.
Neutrophils (NEUT) - Measures neutrophils involved particularly in bacterial defence and inflammation.
Lymphocytes - Measures lymphocytes involved in adaptive immune responses.
Monocytes (MONO) - Measures monocytes involved in immune and inflammatory activity.
Eosinophils (EOSIN) - Measures eosinophils associated with allergy, parasites and selected inflammatory conditions.
Basophils - Measures circulating basophils involved in inflammatory and allergic responses.
Platelets - Measures the cells responsible for primary blood-clot formation.
Factor II Prothrombin - G20210A mutation - Detects a genetic variant associated with increased Prothrombin production and higher venous thrombosis risk.
Factor V Leiden - G1691A mutation - Detects the common Factor V Leiden variant associated with resistance to Activated Protein C and increased venous thrombosis risk.
Cardiolipin Antibodies (IgG+IgM) - Measures antiphospholipid antibodies that can be associated with thrombosis when persistently positive and accompanied by appropriate clinical criteria.
Full Blood Count (with 5 part White Cell Differential) - Provides the combined haematological profile from which the individual red-cell, white-cell and Platelet measurements are reported.
Who May Benefit From the Pre-Travel Screen (DVT) Test?
This screen may be useful before prolonged travel where personal or family history suggests a higher-than-average risk of venous thrombosis.
People with a previous unexplained DVT or pulmonary embolism - Previous thrombosis substantially changes future risk assessment.
People with a strong family history of blood clots - Inherited thrombophilia can occur within families.
People planning frequent or long-haul travel with additional risk factors - Prolonged immobility can compound existing risk.
People using Oestrogen-containing contraception or HRT - Oestrogen-containing treatment can increase venous thrombosis risk.
Pregnant or recently postpartum people planning travel - Pregnancy and the postpartum period increase clotting tendency.
People with a history of recurrent pregnancy loss under specialist assessment - Antiphospholipid antibodies can be clinically relevant in selected cases.
People with a previously abnormal thrombophilia test - Repeat or confirmatory testing may occasionally be appropriate.
People advised by a clinician to investigate inherited thrombosis risk - Genetic testing can clarify selected hereditary risk factors.
How to Prepare
Genetic Factor V Leiden and Prothrombin results are not altered by anticoagulant medication, but other clotting investigations can be affected by treatment or acute thrombosis.
Do not stop anticoagulants without medical instructions.
Symptoms and Reasons to Consider the Pre-Travel Screen (DVT) Test
This is primarily a risk-assessment panel rather than a test for diagnosing a current DVT.
A personal history of venous thrombosis - Previous DVT or pulmonary embolism is an important clinical risk factor.
A first-degree relative with an unexplained clot at a young age - This can raise suspicion of inherited thrombophilia.
Previous thrombosis associated with Oestrogen treatment or pregnancy - Additional inherited risk can occasionally be present.
Recurrent pregnancy loss with suspected antiphospholipid disease - Cardiolipin Antibodies can form part of specialist assessment.
Upcoming prolonged travel combined with several risk factors - Clinical risk assessment can help determine appropriate travel precautions.
New unilateral leg swelling, calf pain, chest pain, sudden breathlessness, coughing blood or collapse can indicate a current DVT or pulmonary embolism.
These symptoms require urgent medical assessment. This screening panel is not a diagnostic test for an acute blood clot.
How to Book Your Pre-Travel Screen (DVT) Test
The Pre-Travel DVT Screen can be booked privately before prolonged travel where additional thrombosis-risk assessment is appropriate.
Choose the Pre-Travel Screen (DVT)
Select the 18-marker DVT risk screen online.
Select your sample collection option
Choose an in-clinic blood draw or professional home or hotel phlebotomy where suitable.
Attend your appointment
A trained healthcare professional collects the required blood samples.
Laboratory analysis
Your samples undergo Full Blood Count, Factor II Prothrombin, Factor V Leiden and Cardiolipin Antibody analysis.
Receive your results securely
Your authorised report is delivered securely and can be reviewed alongside your personal clinical risk factors.
When Will I Receive My Results?
The current London Blood Tests and specialist laboratory listings give a turnaround of approximately 5 days after laboratory receipt.
The genetic thrombophilia components determine much of the overall profile turnaround.
Individual Full Blood Count measurements may be available earlier, but the full screen should be considered complete only when all components are reported.
Understanding Your Results
A screen in which no tested thrombophilia factors are identified means the panel has not detected the particular genetic or antibody risk factors measured.
This does not mean the risk of travel-related DVT is zero.
Age, previous thrombosis, surgery, cancer, pregnancy, medication, mobility and journey duration remain important.
A Factor V Leiden or Prothrombin G20210A variant indicates an inherited tendency associated with increased venous thrombosis risk.
Risk differs according to whether one or two copies of a variant are present and what other clinical risk factors exist.
A positive Cardiolipin Antibody result does not by itself establish antiphospholipid syndrome.
Persistent positivity on repeat testing and an appropriate clinical history are required for diagnosis.
The Full Blood Count should be interpreted separately according to its individual markers.
Why Book With London Blood Tests?
London Blood Tests provides private Pre-Travel DVT screening for people who want selected inherited and autoimmune clotting risks assessed before travel.
Includes common inherited thrombophilia variants - Factor V Leiden and Prothrombin G20210A are assessed.
Includes Cardiolipin Antibodies - These provide information about selected immune-related thrombosis risk.
Includes a Full Blood Count - General red-cell, white-cell and Platelet information is provided.
Relevant before prolonged travel in higher-risk people - The profile can support a more informed clinical risk discussion.
Useful when family history is significant - Inherited variants can occur in multiple relatives.
Genetic results do not change over time - Factor V Leiden and Prothrombin genotype generally need to be established only once.
Professional blood collection - Clinic and suitable home or hotel appointments are available.
Clear pricing - The Pre-Travel Screen (DVT) costs £371.
Private Pre-Travel Screen (DVT) Blood Test in London
London Blood Tests provides private Pre-Travel DVT screening for people requiring additional assessment of selected thrombosis risk factors.
The profile costs £371 and the live catalogue reports 18 biomarkers.
Results are expected approximately 5 days after laboratory receipt.
The profile does not predict whether a traveller will develop a clot and should be interpreted alongside the individual's full clinical risk profile.